The FreeStyle Libre continues to demonstrate its use as a key piece of technology that can improve the management of type 1 and type 2 diabetes in newly released data. Furthermore, Abbott are set to continue the potential of the FreeStyle Libre with an announcement of an exciting new partnership.
The findings have been unveiled today at the International Conference on Advanced Technologies and Treatment for Diabetes (ATTD) 2020, currently taking place in Madrid.
The research has shown that the pioneering device, which is now available on the NHS, improves blood glucose control, increases time in target glucose range and reduces time in hyperglycemia and hypoglycemia.
Not only that but people who rely on the technology also tend to experience much lower HbA1c levels for at least a year after using the FreeStyle Libre.
Dr Mahmood Kazemi, the Divisional Vice President of Global Medical and Scientific Affairs of Abbott’s diabetes care unit, said: “As the world leader in sensor-based glucose monitoring with more than two million users, Abbott’s FreeStyle Libre system has an unmatched body of real-world evidence supporting its clinical benefits.
“Time and time again, we’ve seen meaningful data that reaffirm our technology’s direct impact in achieving better health outcomes for people with diabetes – and the findings at ATTD underscore how we’re continuing to transform people’s lives.”
However, many users of the FreeStyle Libre have experienced recent frustration as sensor supply falls short of demand, leaving people unable to get their hands on replacement sensors. At time of writing, the online shop is still not accepting new customers.
Abbott is striving to create and further innovative diabetes-related technologies. The company has also announced it is partnering up with Insulet, a company that specialises in tubeless insulin pumps.
Both organisations aim to use their market-leading products to create a simple but accurate integrated digital health platform for people with type 1 diabetes.
Shacey Petrovic, Insulet’s President and Chief Executive Officer, added: “We are excited to expand our partnership with Abbott by building on our consumer-centric Omnipod Horizon platform, which offers unparalleled simplicity, accuracy, and now, sensor choice for consumers.
“As interoperability becomes increasingly important, our approach to automated insulin delivery will change the future of blood glucose management by offering consumers greater choice in algorithms, sensors and overall experience. This collaboration furthers our shared vision to help our consumers put diabetes in the background, so they have more freedom to enjoy life.”
